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Take home message: 
Individuals with chronic refractory cough (CRC) are less able to suppress cough during a 
capsaicin cough suppression test (CST). The CST is repeatable, associated with objective cough 
frequency and can distinguish patients with CRC from healthy subjects.  
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ABSTRACT 
Functional brain imaging in individuals with chronic cough demonstrates reduced activation 
in cortical regions associated with voluntary cough suppression. Little is known about the 
ability of patients with chronic cough to suppress cough. This study aimed to compare the 
ability to voluntarily suppress cough during inhaled capsaicin challenge in participants with 
chronic refractory cough with that in healthy controls. This study also aimed to assess the 
repeatability of capsaicin challenge test with voluntary cough suppression. 
Participants with chronic refractory cough and healthy controls underwent inhaled capsaicin 
challenge tests whilst attempting to suppress their cough responses. After 5 days either a 
conventional capsaicin challenge test with no cough suppression attempt, or a repeat test 
with an attempt at cough suppression was performed. Threshold capsaicin concentrations 
required to elicit 1, 2 and 5 coughs were calculated by interpolation. Objective 24-hour cough 
frequency was measured in individuals with chronic refractory cough. 
Healthy controls were able to suppress capsaicin-evoked cough whilst participants with 
chronic refractory cough were not. Geometric mean (SD) capsaicin dose thresholds for 5 
coughs with (CS5) and without (C5) suppression attempts were 254.40 (3.78) vs. 45.89 (3.95) 
mol.L-1 respectively in healthy controls (p=0.033) and 3.34 (5.04) vs 3.86 (5.13) mol.L-1 in 
patients (p=0.922). Capsaicin dose thresholds for triggering 5 coughs with self-attempted 
cough suppression were significantly lower in participants with chronic refractory cough than 
in healthy controls; geometric mean (SD) 4.94 (4.43) vs. 261.10 (4.34) mol.L-1 respectively; 
mean difference (95% CI) 5.72 (4.54-6.91) doubling doses (p<0.001). Repeatability of cough 
suppression test in both patients and healthy controls was high; intraclass correlation 
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coefficients of log(CS5) values 0.81 and 0.87 respectively. CS5 was associated with objective 
cough frequency (=-0.514, p=0.029). 
Participants with chronic refractory cough were less able to voluntarily suppress capsaicin-
evoked cough compared to healthy controls. This may have important implications for the 
pathophysiology and treatment of chronic cough.   
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INTRODUCTION 
Chronic cough, defined as a cough longer than 8 weeks in duration, affects up to 9.6% of the 
population [1, 2]. In up to 42% of patients, the cough remains persistent despite extensive 
investigations and trials of treatment; this is often referred to as chronic refractory cough 
(CRC) [3, 4]. CRC is associated with considerable physical and psychological morbidity [5–7]. 
The mechanism of cough in CRC is unclear. The symptom profile of patients and the 
observation of hypersensitivity to tussive agents, such as capsaicin, had led to the hypothesis 
that CRC is a disorder of dysfunctional airway sensory nerves and their central processing [8, 
9]. In 2004, Eccles [10], and more recently Hegland et al. in 2012 [11], proposed that the 
voluntary suppression of cough is also an important mechanism in the regulation of cough. 
Ando et al. have demonstrated using functional neuroimaging in chronic cough that there is 
reduced activity in forebrain regions including the dorsomedial, prefrontal and anterior mid-
cingulate cortices [12]. These same areas appear engaged in the voluntary suppression of 
capsaicin-evoked cough [12–14]. 
 
Cough suppression can be studied by modifying the capsaicin challenge test to ask 
participants to attempt to prevent themselves from coughing following inhalation of the 
tussive agent [15, 16]. Although this technique has demonstrated that healthy subjects can 
suppress capsaicin-evoked cough [15], little is known about whether those with CRC can do 
the same. We hypothesised that patients with CRC are less able to voluntarily suppress cough 
during a capsaicin challenge test compared to healthy subjects.  
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We investigated the feasibility and repeatability of a cough suppression test in participants 
with CRC and healthy subjects. We investigated and compared the ability of self-attempted 
cough suppression during capsaicin challenge test between participants with CRC and healthy 
controls. We also investigated the relationship of the ability to suppress cough with 24-hour 
objective cough frequency and health status. Lastly, we investigated the ability of the cough 





Patients with chronic refractory cough (>8 weeks duration) were recruited prospectively from 
a tertiary care specialist cough clinic (King’s College Hospital, London, UK). The diagnosis of 
chronic refractory cough was assessed by clinicians according to the British Thoracic Society 
guidelines for the management of chronic cough in adults [17]. Inclusion criteria were a 
diagnosis of chronic cough, either unexplained or refractory to treatment of a known 
potential cause, and a normal chest radiograph. Exclusion criteria were the presence of 
another chronic respiratory disease, use of angiotensin-converting enzyme inhibitor 
medication within the last 12 months, current smoking, smoking within the last 12 months 
and upper respiratory tract infection within the last four weeks.  
 
Healthy controls were recruited prospectively through local advertisement. Exclusion criteria 
were identical to those for participants with chronic refractory cough with the addition of the 
 8 
presence of cough in the last 8 weeks, and a ratio of forced expiratory volume in 1 second 
(FEV1) to forced vital capacity (FVC) <0.7. All participants gave informed written consent. The 
study was granted research ethics committee approval (NRES East London and The City, 
10/H0703/6). All participants provided written informed consent for participation in the 
study. All ethical elements of the study conformed to the Declaration of Helsinki.  
 
Protocol 
Participants had no prior exposure to a capsaicin challenge test. Participants underwent 
investigations over two visits. At Visit 1, demographic and anthropometric data were 
collected. All participants underwent spirometry and a modified capsaicin challenge test with 
attempts at voluntary cough suppression, ‘cough suppression test’. Participants with CRC also 
completed subjective assessments of cough severity, urge to cough, cough-specific quality of 
life, anxiety and depression. Participants with CRC were invited to undergo 24-hour objective 
cough monitoring. At Visit 2, which followed Visit 1 by 5 days, participants were selected at 
random to undergo either a standard capsaicin challenge test without attempting to suppress 
coughing or a repeat cough suppression test (Figure E1). An interval of 5 days was chosen 
between Visits 1 and 2 to avoid the potential for tachyphylaxis to capsaicin [18].  
 
Capsaicin challenge test 
Cough reflex sensitivity was assessed as per recommendations by the European Respiratory 
Society guidelines [19]. Capsaicin (Sigma-Aldrich, Missouri, USA) solution was administered 
as 10 µL single breath inhalations via an air-powered dosimeter (KoKo Digidoser, nSpire 
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Health Inc, Colorado, USA) at increasing doubling doses (0.49-1000 µmol.L-1) at 1-minute 
intervals. 0.9% saline solutions were randomly interspersed to reduce the effect of 
anticipation [19, 20]. A single characterised nebuliser (DeVilbiss Healthcare, New York, USA) 
with an output of 1.205 mL.min-1 was utilised for all participants throughout the study. A valve 
was utilised to restrict the inspiratory flow to 0.5 L.s-1 [19, 21]. A minimum of 3 respiratory 
cycles were performed prior to the administration of each solution. The inspiratory-expiratory 
flow-volume signals were inspected in real-time by 2 operators (PC, HF) to ensure a consistent 
inspiratory effort throughout the administration of the nebulised solution. If the participant 
did not take a full inhalation as observed during the real-time visual display of the flow-
volume signal, the test was repeated. The number of coughs elicited by each inhalation was 
counted with the aid of a digital audio recorder (ICD-PX333, Sony Corporation, Tokyo, Japan) 
for 15 s after each dose administration [19, 21]. The challenge test continued until ≥5 coughs 
were elicited by a single inhalation of solution.  
 
Modified capsaicin tussive challenge (’cough suppression test’) 
The ability to suppress cough was assessed by modifying the capsaicin challenge test; 
participants were instructed, “Please do not cough during the test”. The capsaicin 
concentrations required to elicit ≥1 cough (CS1), ≥2 coughs (CS2) and ≥5 coughs (CS5) were 
recorded. 
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Standard capsaicin tussive challenge (without self-attempted cough suppression) 
During a standard capsaicin challenge test, participants were instructed, “Please cough if you 
wish during the test”. The capsaicin concentrations required to elicit ≥1 cough (C1), ≥2 coughs 
(C2) and ≥5 coughs (C5) were recorded.  
 
Cough frequency monitoring 
Cough frequency was recorded for 24 hr with the Leicester Cough Monitor (LCM) [22]. The 
LCM is a validated ambulatory cough monitoring system which consists of an MP3 audio 
recorder (ICD-PX333, Sony Corporation, Tokyo, Japan), free-field microphone (LFH9173, 
Philips, Amsterdam, Netherlands) and cough detection software [22]. Coughs were detected 
as single events regardless if they occurred in isolation or in bouts [22]. Both awake cough 
counts (number of coughs per estimated time spent awake) and awake daily cough frequency 
(coughs.hr-1) were documented. The participants were requested to record and report their 
time spent asleep.  
 
Subjective assessments 
Cough severity, urge to cough and health status 
Cough severity and urge to cough were recorded on visual analogue scales (VAS) (range 0-100 
mm; higher scores indicating more severe cough and more severe urge respectively) [19]. The 
health status of the participants with CRC was recorded with the Leicester Cough 
Questionnaire (LCQ), which is a validated self-administered questionnaire for cough-specific 
health status in chronic cough (range 3-21; higher scores indicating better health status) [23].  
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Depression and anxiety 
The Patient Health Questionnaire (PHQ9) was used to assess the severity of depression (range 
0-27; higher scores indicate more severe depression) [24]. The Generalised Anxiety Disorder 
Assessment (GAD7) (range 0-21; higher scores indicate more severe anxiety), a validated self-
administered questionnaire, was utilised to assess the severity of generalised anxiety [25].  
 
Lung function 
Spirometry (Jaeger MS-PFT Analyser Unit with Sentry Suite software version 2.19.96) was 
measured according to the guidelines by the European Respiratory Society guidelines and the 
American Thoracic Society [26]. 
 
Statistical analysis  
The distribution of data was assessed using the D’Agostino-Pearson test. Parametric data 
were expressed as mean (standard deviation, SD) whereas non-parametric data were 
expressed as median (interquartile range, IQR). The capsaicin challenge and cough frequency 
data were presented as geometric mean (geometric standard deviation, SD). Parametrically 
distributed data were analysed with paired t-test to compare sample means for paired data, 
and independent unpaired Welch’s t-tests to compare sample means for unpaired data. 
Comparison of non-parametric data was carried out using the Wilcoxon matched-pairs signed 
rank test for paired data, and Mann-Whitney U test for unpaired data. Fisher’s exact test and 
Chi-squared test were utilised for categorical data. Correlations between variables were 
analysed with Spearman’s correlation coefficient (ρ) for non-parametric data. Repeatability 
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was assessed using the Bland-Altman method and intraclass correlation coefficients (ICC) 
based on a single-rater, absolute agreement, two-way mixed-effects model. 
 
The concentrations of capsaicin required to elicit 1, 2 and 5 coughs were calculated by 
interpolation of the log dose-response curve [8]. A value of 1000 µmol.L-1 was assigned to any 
interpolated values which were >1000 µmol.L-1. Standard capsaicin provocation test 
endpoints were expressed as C1, C2 and C5, which were the capsaicin concentrations 
required to elicit 1, 2 and 5 coughs respectively. Cough suppression test endpoints were 
expressed as CS1, CS2 and CS5; the respective capsaicin concentrations required to elicit 1, 2 
and 5 coughs whilst participants attempted to self-suppress coughing. 
 
The sensitivity and specificity of the cough suppression test and standard capsaicin challenge 
test for distinguishing patients with cough from healthy controls were analysed using 
receiver-operator characteristic (ROC) curve analysis. Youden’s index was used to identify the 
optimal threshold [27]. P-values <0.05 were considered statistically significant.  
 
From a previous study, we expected 10 or more participants to be a sufficient sample size for 
making intra-individual comparisons in a tussive challenge test [21]. Therefore, a minimum of 
10 patients and controls were needed for each test option in Visit 2. We therefore aimed to 
recruit a sample size of 20-30 participants with CRC and healthy controls.  
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All analyses were performed on Prism® Version 7.0c (GraphPad Software, San Diego, 
California, USA), except the Bland-Altman, intraclass correlation correlations and ROC curves 
analyses which were performed on RStudio® Version 1.1.383 (RStudio Inc, Boston, 




Thirty consecutive participants with CRC were recruited and compared with 23 healthy 
controls; demographics, anthropometrics, spirometry and clinical characteristics are shown 
in Table 1. There was no significant difference in age and gender between the participants 
with CRC and the healthy controls (Table 1). The median (IQR) duration of cough in 
participants with CRC was 7.0 (2.3-20.0) years. No participants in the study had a clinical 
diagnosis of depression or anxiety. A subgroup of 11 participants with CRC and 13 healthy 
controls underwent the standard capsaicin provocation test, permitting coughing ad libitum, 
at a second visit. A subgroup of 13 participants with CRC and 10 healthy controls returned for 
a second visit to investigate the repeatability of the cough suppression test. 
 
Cough suppression test 
When attempting to suppress cough, capsaicin cough thresholds (CS1, CS2 and CS5) were 
significantly lower in participants with CRC compared to healthy controls (Table 2 and Figure 
1). The mean difference (95% CI) in CS5 between participants with CRC and healthy controls 
was 5.72 (4.54-6.91) doubling doses (p<0.001) (Table 2 and Figure 1).  
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Standard capsaicin cough challenge  
When not attempting to suppress cough, participants with CRC again had significantly lower 
cough thresholds (C1, C2 and C5) than healthy controls (Table 2). The mean difference (95% 
CI) in C5 between participants with CRC and healthy controls was lower than the difference 
in CS5 between groups at 3.66 (1.80-5.52) doubling doses (p<0.001) (Table 2). 
 
Healthy participants were able to suppress capsaicin-induced cough; a significant increase in 
the concentration of capsaicin required to elicit 1, 2 and 5 coughs when asking subjects to 
attempt cough suppression compared to allowing coughing as desired: geometric mean (SD) 
CS5 vs. C5: 261.1 (4.34) vs. 45.89 (3.95) µmol.L-1; mean difference (95% CI) 2.77 (1.25-4.28) 
doubling doses (p=0.033) (Figure 2a). In contrast, participants with CRC were unable to 
suppress capsaicin-induced cough as similar capsaicin thresholds in both tests were 
demonstrated: geometric mean (SD) CS5 vs. C5: 4.94 (4.43) vs. 3.86 (5.13) µmol.L-1; mean 
difference (95% CI) -0.21 (-1.37-0.96) doubling doses (p=0.922) (Figure 2b).  
 
Repeatability of cough suppression  
In healthy controls, the intraclass correlation coefficients (ICC) for repeatability of log(CS1), 
log(CS2) and log(CS5) were 0.64, 0.83 and 0.87 respectively (Table 3). The mean difference 
(95% CI) in CS5 in healthy controls was 0.04 (-0.47 to 0.54) doubling doses over 5 days (Figure 
3a). The ICCs for repeatability of log(CS1), log(CS2) and log(CS5) in participants with chronic 
refractory cough were 0.13, 0.24 and 0.81 respectively (Table 3). The mean difference (95% 
CI) in CS5 in participants with CRC was 0.42 (-1.37-2.22) doubling doses over 5 days (Figure 
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3b). CS5 was considered the most repeatable endpoint in both healthy controls and 
participants with CRC. There was no evidence that the outcome of the first cough suppression 
test influenced the second. 
 
Relationship between cough suppression ability and daily cough frequency  
Eighteen participants with CRC agreed to undergo 24-hour cough monitoring. The geometric 
mean (SD) awake cough count was 351.2 (2.6) coughs over a 24-hour period (Table 1). There 
were significant correlations between awake cough counts and CS1, CS2 and CS5 (=-0.556, 
p= 0.017; =-0.551, p=0.018; and =-0.514, p=0.029, respectively) (Figure 4).  
 
Subjective assessments 
Cough severity, urge to cough and health status 
Participants with CRC had mean (SD) cough severity VAS scores 74.8 (18.7) mm, median (IQR) 
urge to cough VAS scores 74.2 (18.4) mm and mean (SD) LCQ total scores 10.1 (5.7). There 
was no association between voluntary cough suppression test thresholds (CS1, CS2 and CS5) 
and either cough severity, urge to cough, or health status scores (Table E1).  
 
Depression and Anxiety 
The median (IQR) PHQ9 and GAD7 scores for participants with CRC were 1 (0-8) and 1 (0-9) 
respectively (Table 1). Sixty percent participants reported no depressive symptoms on the 
PHQ9 whilst 26%, 7% and 7% participants reported mild, moderate and severe depressive 
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symptoms respectively. Seventy four percent participants with CRC reported no anxiety on 
the GAD7 whilst 13% and 13% participants reported mild and severe anxiety symptoms 
respectively. There was no correlation between cough suppression thresholds (CS1, CS2 and 
CS5), and either PHQ9 or GAD7 scores (=0.117-0.438, p=0.104-0.676). 
 
Optimal capsaicin cough thresholds to distinguish participants with CRC from healthy 
controls 
CS5 was the most repeatable cough suppression endpoint and was therefore selected for 
further analyses (Figure 2 and Table 3). The optimal thresholds for CS5 and C5 according to 
Youden’s index were 38.86 µmol.L-1 (sensitivity=100.0% and specificity=91.3%) and 12.59 




We investigated the ability of patients with CRC to suppress their cough during a capsaicin 
challenge test. Patients with CRC were unable to suppress capsaicin-invoked cough compared 
to healthy subjects. The CS5 measure of cough suppression was highly repeatable and 
significantly more repeatable than CS1 and CS2. CS5 was associated with 24-hour objective 
cough frequency in patients with chronic refractory cough. CS5 was better than C5 for 
distinguishing patients with CRC from healthy controls; a threshold of 39 mol.L-1 had a high 
sensitivity and specificity.  
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The key finding from our study was that patients with CRC were less able to suppress capsaicin 
evoked cough compared to healthy subjects. In a small study investigating the effects of 
mindfulness meditation on cough, Young et al also demonstrated that patients with CRC could 
not suppress their cough as effectively as healthy subjects [28]. An impairment in the ability 
to suppress cough suggests an abnormality in central neural pathways in patients with CRC. 
A recent study by Ando et al utilising functional MRI scan imaging found reduced activity in 
the dorsomedial pre-frontal cortex and anterior mid-cingulate cortices in the brain in patients 
with CRC when they were asked to suppress the urge to cough [12]. Ando et al, proposed that 
a reduced capacity to suppress cough motor behaviour was an important component of the 
central neurobiology of cough hypersensitivity as well as the amplification of cough sensory 
inputs [12]. A better understanding of the central neural mechanisms of cough may yield 
novel targets for developing antitussive therapy. It is likely that some patients will benefit 
from antitussive therapy that target central rather than peripheral mechanisms. Inhibitors of 
the sensory nerve P2X3 ion channel (MK7264) are the most promising peripherally acting 
antitussive therapy in development, but they are not effective in 30-40% of subjects and, in 
those who benefit, the frequency of cough often does not return to normal levels [29]. There 
is a wide range of peripheral cough receptors and sensory nerves that mediate cough, and 
therefore it is likely that targeting one pathway will not benefit all patients [30]. Anti-tussive 
therapies that act centrally to inhibit the amplification of cough or enhance the activity of 
inhibitory neurons and their mediators have the advantage of intervening at a level where 
multiple peripheral inputs converge. Speech therapy and physiotherapy interventions that 
train patients to suppress their cough have yielded encouraging results [31, 32]. A recent 
randomised controlled trial of Physiotherapy and Speech & Language Therapy Intervention 
(PSALTI) led to a 41% reduction in cough frequency and an improvement in health-related 
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quality of life [32]. Morphine is an effective antitussive in a subgroup of patients with CRC 
[33]. It is likely that morphine acts centrally but it is not known whether it mediates its action 
by acting on cough amplification or inhibitory pathways. Morphine is associated with side 
effects such as drowsiness which limits its use. A better understanding of the central 
mechanisms of cough may yield new therapeutic targets with a better side effect profile.  
  
The healthy subjects in our study were able to suppress their cough during a tussive challenge 
test and this was consistent with the findings of Hutchings et al [15]. A study by Bickerman et 
al in 1956 however reported that the cough response following an initial challenge diminishes 
when the challenge is repeated [34]. This was not tachyphylaxis since the tests were 
performed on separate days. This finding has not been confirmed in subsequent, larger 
studies by Wright et al and Dicpinigaitis et al, both reporting no significant reduction in cough 
during sequential challenges [21, 35]. A potential explanation for the contrasting findings is 
differences in the equipment used and methodology between the studies. Wright et al 
compared tussive challenges using a dosimeter with and without an inspiratory flow regulator 
valve, and found that a diminished cough response with sequential challenges was associated 
only with the dosimeter with unregulated inspiratory flow [35]. It is possible that subjects in 
the Bickerman et al study became aware of the stimulus after the initial challenge and that 
the challenge can become unpleasant at high concentrations of tussive agent. Thus the 
subject, through a learned response, on subsequent inhalations may not have inhaled as 
strongly as they did first [34, 35]. This is not possible with the KoKo digidoser we used in our 
study because inspiratory flow is regulated and limited [8, 21]. The flow-volume signals were 
inspected in real time by 2 of the investigators for each inhalation during all tussive 
 19 
challenges. Furthermore, we found CS5 to be highly repeatable, and there was no effect of 
the order in which challenges were performed. This is further supported by the lack of a test 
order effect on the cough suppression thresholds in healthy individuals in the study by 
Hutchings et al [15]. We also explored the potential for anxiety and mood to influence the 
ability of subjects to suppress cough. There was no association between CS5 and mood and 
anxiety levels assessed with validated tools.   
 
Cough in chronic respiratory disease may be driven by several mechanisms such as cough 
reflex hypersensitivity, airway hyperresponsiveness and airway inflammation [36]. The 
identification of the mechanism of cough may be useful to target specific therapy and avoid 
unnecessary trials of treatment [37]. Cough provocation tests are an objective measure of 
cough reflex sensitivity but their use in clinical practice has been limited by several factors, 
one being that they poor at discriminating patients with cough hypersensitivity syndrome 
from healthy subjects [8, 38]. To our knowledge, our study is the first to demonstrate that 
modifying the standard capsaicin tussive challenge by requesting that subjects attempt to 
suppress their cough makes it a better discriminator of patients with CRC from healthy 
subjects. The cough suppression test endpoint CS5 threshold of 39 mol.L-1 had a high 
sensitivity and specificity for discriminating between patients with CRC and healthy subjects.  
Further studies of the CS5 measure in a range of respiratory disorders, such as chronic 
obstructive pulmonary disease, asthma and idiopathic pulmonary fibrosis, are needed to 
investigate the clinical and diagnostic usefulness of cough suppression tests. The potential for 
the cough suppression test to identify patients who respond to centrally acting therapies, 
such as opiates, should also be investigated. 
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There are limitations with our study. We studied a relatively small sample size. The order of 
the capsaicin challenge test with and without voluntary suppression was not randomised.     
We did however enrol consecutive patients and, furthermore, there was no significant order 
effect of the voluntary cough suppression test in the repeatability study. We studied CS5 at 
the first visit to avoid the potential influence of prior tussive challenges. We found no 
significant association between CS5 and a subjective measure of health-related quality of life. 
This may be partly due to the small sample size of our study but this observation is also 
consistent with numerous studies that have reported a poor correlation between subjective 
and objective measures of cough [38, 39]. Cough reflex sensitivity and health related quality 
of life are very different dimensions of cough and as such they are expected to correlate 
poorly. The sensitivity for C5 to discriminate patients with CRC from healthy controls was 
lower in our study compared to that reported by Pullerits et al [40]. This may be due to 
differences in the study populations and sample sizes; Pullerits et al recruited participants 
who had other airway symptoms in addition to cough and they were pre-selected for hyper-
reactivity to capsaicin [40]. 
 
In conclusion, patients with CRC are unable to suppress their cough during a capsaicin cough 
challenge test compared to healthy controls. CS5 is a highly repeatable measure and is 
associated with objective 24-hour cough frequency. CS5 has a high sensitivity and specificity 
for distinguishing patients with CRC from healthy controls. Further studies should investigate 
the neural pathways involved in inhibiting cough, as this may identify new targets for the 
development of anti-tussive therapy. 
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Table 1. Demographics, anthropometrics and clinical characteristics of participants with 
chronic refractory cough and healthy controls 





Age (years) 59.9 (9.5) 54.5 (11.4) 0.072† 
Gender (female) 27 (90%) 19 (83%) 0.443‡ 
BMI (kg.m-2) 28.7 (4.9) 25.7 (4.1) 0.019† 
Smoking status   0.615§ 
Current 0 (0) 0 (0)  
Ex 11 (37) 10 (43)  
Never 19 (63) 13 (57)  
Spirometry    
FEV1 % predicted  97.3 (22.9) 100.7 (12.4) 0.243† 
FVC % predicted 104.6 (29.5) 109.0 (13.9) 0.689† 
Duration of cough (years) 7.0 (2.3-20.0) N/A  
24-hour cough monitoring  N/A  
Awake cough counts 
(coughs)* 
351.2 (2.6)   
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Awake cough frequency 
(coughs.hour-1)* 
24.8 (2.2)   
Cough severity VAS (mm) 75.1 (19.0) N/A  
Urge to cough VAS (mm) 74.2 (18.4) N/A  
LCQ  N/A  
Physical 3.7 (2.0)   
Psychological 3.1 (2.0)   
Social 3.0 (2.0)   
Total 9.8 (5.7)   
PHQ9 1 (0-8) N/A  
GAD7 1 (0-9) N/A  
 
Data presented as mean (SD), median (IQR) or absolute values (percentage). 
BMI = body mass index; FEV1 = forced expiratory volume in 1 second; FVC = forced vital 
capacity; VAS = visual analogue scale and LCQ = Leicester Cough Questionnaire; PHQ9 = 
Patient Health Questionnaire and GAD7 = Generalised Anxiety Disorder Assessment 
*Geometric mean (SD) 
†Welch’s t-test 
‡Fisher’s exact test 
§Chi-squared test 
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Table 2. Capsaicin dose thresholds with and without self-attempted cough suppression during 
tussive challenge tests in participants with chronic refractory cough and healthy controls 
 Chronic 
refractory cough  
Healthy controls  p values* 
With self-attempted cough 
suppression 
(n=30) (n=23)  
CS1 (mol.L-1) 2.01 (3.40) 40.34 (6.64) <0.0001 
CS2 (mol.L-1) 2.52 (3.44) 71.52 (6.06) <0.0001 
CS5 (mol.L-1) 4.94 (4.43) 261.10 (4.34) <0.0001 
Without self-attempted cough 
suppression 
(n=11) (n=13)  
C1 (mol.L-1) 0.91 (5.17) 7.20 (2.82) 0.0012 
C2 (mol.L-1) 1.31 (4.89) 11.44 (2.82) 0.0015 
C5 (mol.L-1) 3.86 (5.13) 45.89 (3.95) 0.0004 
Data presented as geometric mean (SD) 
CS1, CS2, CS5 = capsaicin concentrations to elicit 1, 2 and 5 coughs during self-attempted 
suppression of coughing respectively; C1, C2, C5 = capsaicin concentrations to elicit 1, 2 and 
5 coughs without self-attempted cough suppression respectively.  
*Mann-Whitney U test  
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Table 3. Repeatability of self-attempted cough suppression in participants with chronic 
refractory cough and healthy controls 
 Day 1 Day 5 ICC 
(Repeatability) 
Chronic refractory cough 
CS1 (mol.L-1) 2.00 (4.69) 1.27 (17.44) 0.13 
CS2 (mol.L-1) 2.71 (4.00) 2.08 (9.38) 0.24 
CS5 (mol.L-1) 6.79 (4.17) 9.11 (4.02) 0.81 
Healthy controls 
CS1 (mol.L-1) 40.17 (4.13) 69.53 (4.18) 0.56 
CS2 (mol.L-1) 96.08 (1.18) 89.83 (4.37) 0.76 
CS5 (mol.L-1) 361.60 (2.87) 370.90 (3.09) 0.87 
 
Data presented as geometric mean (SD) 
ICC = intra-class correlation coefficient; CS1, CS2, CS5 = capsaicin concentrations to elicit 1, 2 
or 5 coughs with self-attempted cough suppression respectively 
  
 34 
Table E1. The relationship of capsaicin tussive challenge tests with self-attempted cough 
suppression with cough severity, urge to cough visual analogue scale, and cough-specific 
health status in participants with chronic refractor cough 
 CS5 (n=30) 
 Correlation coefficients p values 
Cough severity VAS -0.260 0.173 
Urge to cough VAS -0.118 0.542 
LCQ   
Physical -0.015 0.938 
Psychological -0.098 0.614 
Social -0.164 0.395 
Total -0.094 0.627 
 
All correlation coefficients are Spearman’s rank correlation 




Table E2. The sensitivity and specificity of capsaicin cough challenge test thresholds for 
discriminating patients with chronic refractory cough from healthy subjects  
a) Cough suppression test (CS5) 
Thresholds Sensitivity (%) Specificity (%) 
999.93 100.00 26.09 
867.36 100.00 39.13 
585.04 100.00 43.48 
407.20 100.00 47.83 
314.58 100.00 52.17 
244.18 100.00 56.52 
218.41 100.00 60.87 
164.67 100.00 65.22 
125.13 100.00 69.57 
96.83 100.00 73.91 
68.38 100.00 78.26 
56.83 100.00 82.61 
45.27 100.00 86.96 
38.86 100.00 91.30 
37.13 96.67 91.30 
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34.23 93.33 91.30 
31.92 90.00 91.30 
30.68 86.67 91.30 
29.92 83.33 91.30 
24.70 83.33 95.65 
19.34 80.00 95.65 
18.56 76.67 95.65 
16.85 73.33 95.65 
15.58 70.00 95.65 
14.73 66.67 95.65 
13.89 63.33 95.65 
12.37 60.00 95.65 
10.21 56.67 95.65 
8.09 53.33 95.65 
6.40 50.00 95.65 
5.85 50.00 100.00 
5.30 46.67 100.00 
4.15 43.33 100.00 
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2.57 40.00 100.00 
1.91 36.67 100.00 
1.80 33.33 100.00 
1.59 30.00 100.00 
1.36 26.67 100.00 
1.13 23.33 100.00 
0.94 20.00 100.00 
0.86 16.67 100.00 
0.77 13.33 100.00 
0.63 10.00 100.00 
0.51 6.67 100.00 
 
